ArticleFrontiers in neurology2025
Safety and efficacy of tirofiban after intravenous thrombolysis with urokinase in patients with acute ischemic stroke.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tirofiban combined with alteplase thrombolysis or endovascular therapy has been proven to improve the prognosis of patients with acute ischemic stroke (AIS). Some patients, due to the extended time window beyond 4 h and economic considerations, opt for urokinase thrombolysis instead of alteplase thrombolysis in China. However, there is currently limited research on the use of urokinase thrombolysis bridged with tirofiban. Methods: We employed propensity score match to pair 80 sets of patients from a total of 196 individuals who underwent urokinase thrombolysis for acute ischemic stroke. The study analyzed the 14-day National Institutes of Health Stroke Scale (NIHSS), 90-day modified Rankin Scale (mRS), bleeding events, and compared the odds ratio (OR) of patients with mRS scores of 0-2 within the subgroups. Results: The results show that the NIHSS at 14 days of the tirofiban group was significantly lower than that of the dual antiplatelet group. No significant difference was found in the proportion of patients with mRS score 0-2. The odds ratios were slightly different in subgroups classified with or without previous stroke and hypertension. Discussion: It was confirmed that the tirofiban might be safe in AIS patients received tirofiban after urokinase thrombolysis and could improve short-term neurological function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.